Objective Responses Observed in Heavily-pretreated Ovarian Cancer Patients Treated with Navicixzumab Monotherapy
REDWOOD CITY, Calif., Sept. 24, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that the results of its Phase 1a study with single-agent navicixizumab in patients with refractory solid tumors were published in Investigational New Drugs. The results showed that 19 of the 66 patients with various types of refractory solid tumors had tumor shrinkage following treatment with navicixizumab. Notably, 3 of the 12 (25%) ovarian cancer patients treated in the trial achieved a partial response with single-agent navicixizumab therapy. Navicixizumab is a bispecific antibody that was designed to enhance the anti-tumor effect observed with inhibition of DLL4 or VEGF alone.
"These study results demonstrate that navicixizumab has single-agent anti-tumor activity in several tumor types and is particularly active in heavily pretreated ovarian cancer, a cancer with limited treatment options," said John Lewicki, Ph.D., President and Chief Executive Officer of OncoMed. "We look forward to presenting interim data from our Phase 1b study, which is evaluating navicixizumab in combination with paclitaxel in patients with heavily pretreated platinum-resistant ovarian cancer at the upcoming European Society of Medical Oncology meeting."
Read More: http://cms2.oncomed.com/investors/static-files/176ae2d5-55fe-4627-ade0-61582eb12bde
Cigna Announces Cigna Ventures with $250 Million to Fund Transformative Innovation and Growth for Health Care
BLOOMFIELD, Conn.--(BUSINESS WIRE)--Today, global health service company Cigna (NYSE: CI) announced the launch of Cigna Ventures, a corporate venture fund focused on transformative and innovative health care companies.
Omada Health made its name with its technology. Now it’s luring insurers with operational innovation
Via: Fierce Healthcare
Inside the San Francisco offices of Omada Health, there’s a tongue-in-cheek term used to describe the company: provendor.